Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

• Published in: Nature medicine Vol. 26; no. 11; pp. 1733 - 1741
• Main Authors: Motzer, Robert J., Robbins, Paul B., Powles, Thomas, Albiges, Laurence, Haanen, John B., Larkin, James, Mu, Xinmeng Jasmine, Ching, Keith A., Uemura, Motohide, Pal, Sumanta K., Alekseev, Boris, Gravis, Gwenaelle, Campbell, Matthew T., Penkov, Konstantin, Lee, Jae Lyun, Hariharan, Subramanian, Wang, Xiao, Zhang, Weidong, Wang, Jing, Chudnovsky, Aleksander, di Pietro, Alessandra, Donahue, Amber C., Choueiri, Toni K.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.11.2020; Nature Publishing Group
• Subjects: 631/67/589/1588/1351; 692/308/53; Adolescent; Adult; Aged; Analysis; Angiogenesis; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antigenic determinants; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Apoptosis; Axitinib; Axitinib - administration & dosage; Axitinib - adverse effects; Biological markers; Biomarkers; Biomarkers, Tumor - genetics; Biomedical and Life Sciences; Biomedicine; Cancer Research; Carcinoma, Renal cell; Carcinoma, Renal Cell - drug therapy; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - pathology; Care and treatment; Cell death; Development strategies; Drug therapy; Female; Gene expression; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immunomodulation; Immunomodulators; Immunotherapy; Infectious Diseases; Inhibitor drugs; Kidney - drug effects; Kidney - pathology; Kidney cancer; Male; Metabolic Diseases; Middle Aged; Molecular Medicine; Monoclonal antibodies; Neurosciences; Nucleotides; PD-1 protein; PD-L1 protein; Progression-Free Survival; Renal cell carcinoma; Single-nucleotide polymorphism; Sunitinib - administration & dosage; Sunitinib - adverse effects; Targeted cancer therapy; Testing; Transcriptome; Tumors; Young Adult; United States

We report on molecular analyses of baseline tumor samples from the phase 3 JAVELIN Renal 101 trial ( n  = 886; NCT02684006 ), which demonstrated significantly prolonged progression-free survival (PFS) with first-line avelumab + axitinib versus sunitinib in advanced renal cell carcinoma (aRCC). We fo...